Is Cocrystal Pharma, Inc. (COCP) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 13.0% / 30% | 70.8% / 30% | 8.7% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 13.0% / 33% | 70.8% / 33% | 8.7% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 13.4% / 33% | 73.3% / 33% | 9.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 13.0% / 33% | 70.8% / 33% | 8.7% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 13.4% / 33% | 73.3% / 33% | 9.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -94.9% | |
| Return on Assets (ROA) | -45.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$16M |
| Total Debt | $2M |
| Debt-to-Equity | 20.6 |
| Current Ratio | 5.8 |
| Total Assets | $13M |
Price & Trading
| Last Close | $1.03 |
| 50-Day MA | $1.02 |
| 200-Day MA | $1.24 |
| Avg Volume | 71K |
| Beta | 1.2 |
|
52-Week Range
$0.86
| |
About Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Cocrystal Pharma, Inc. (COCP) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Cocrystal Pharma, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Cocrystal Pharma, Inc.'s debt ratio?
Cocrystal Pharma, Inc.'s debt ratio is 13.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 13.4%.
What are Cocrystal Pharma, Inc.'s key financial metrics?
Cocrystal Pharma, Inc. has a market capitalization of $14M. Return on equity stands at -94.9%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.